A Phase 1 interventional study of Aramchol and Aramchol in Healthy, sponsored by Galmed Medical Reserch. Completed at 1 site in Israel. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-11-03.
Sponsored by Galmed Medical Reserch · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Hypercholesterolemia with a site in Israel — 4 open to participants now, 10 under way, 9 of them phase 3. Hypercholesterolemia · Israel.
Among the 43 studies in Hypercholesterolemia with a site in Israel, this one is the 36th largest by enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2008, is the only one in phase 1, and was the 14th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →4 of the 43 studies in Hypercholesterolemia with a site in Israel are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Israel, United States, Bulgaria and 8 more countries
Ages 18–130
Novartis Pharmaceuticals · Sites in Israel, United States, Argentina and 20 more countries
Ages 6–11
LIB Therapeutics LLC · Sites in Israel, United States, New Zealand and 3 more countries
Ages 6–17
LIB Therapeutics LLC · Sites in Israel, United States, India and 3 more countries
Ages 10+
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 50 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 32 · Phase 4 4
First in 2005; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 573 across the 42 interventional studies, 847 across the 1 observational. Of the 30 that completed or were terminated, 22 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 43 have an industry lead sponsor. The 10 most frequent:
Galmed Medical Reserch is the lead sponsor of 2 studies on the registry; none are open to participants now.
Galmed Medical Reserch has 1 study filed under Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
3 of the studies in Hypercholesterolemia with a site in Israel that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT07619131Phase 3AstraZenecaA Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients. | 2027-07-30 |
| NCT05399992Novartis PharmaceuticalsStudy Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD | 2026-11-23 |
Add all 3 to your calendar (.ics) → With an account.
Among the 43 studies in Hypercholesterolemia with a site in Israel, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers.
Primary Objectives:
Number of Subjects:
Total: A total of 46 healthy subjects will be enrolled. Part A: Sixteen (16) subjects will participate in four, 8-person dosing periods. Each cohort will be alternately dosed twice.
Part B: Thirty (30) subjects will be enrolled in two, 15-person dose-ascending cohorts.
Main Inclusion Criteria:
Part A: Healthy male volunteers aged 18-50 (inclusive) years who have provided written informed consent Part B: Mildly overweight (25\<BMI\<33), with fasting cholesterol levels of 200-300 mg/% or LDL 100-180 mg/% and triglycerides \< 200 mg/%, otherwise healthy male volunteers aged 18-50 (inclusive) years, who have provided written informed consent
Inclusion Criteria:
Major Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo control single dose
Drug: Aramchol
Dose 30 mg
Drug: Aramchol
Dose 100 mg
Drug: Aramchol
Dose 300 mg
Drug: Aramchol
Dose 900 mg
Drug: Aramchol
Dose 30 mg for 4 days
Drug: Aramchol
Dose high for 4 days
Drug: Aramchol
1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)
Also known as: 3β-arachidylamido-7α,12α,dihydroxy 5β-cholan-24-oic acid), fatty-acid bile-acid conjugate
Oral Aramchol at dose 30 mg to 900 mg
Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days
To assess safety and tolerability and Pharmacokinetics of Aramchol at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, subjects receiving multiple doses (Part B)
Time frame: day 1 to 6
To assess and characterize the drug effect on lipid profile and functional pharmacodynamics following single and multiple dose administrations.
Time frame: day 1 to 6
The record gives a start of Sep 2008, a primary completion of Sep 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aramchol
Galmed Medical Reserch